"Drug Repositioning" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The deliberate and methodical practice of finding new applications for existing drugs.
| Descriptor ID |
D058492
|
| MeSH Number(s) |
E05.295.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Repositioning".
Below are MeSH descriptors whose meaning is more specific than "Drug Repositioning".
This graph shows the total number of publications written about "Drug Repositioning" by people in this website by year, and whether "Drug Repositioning" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 1 | 2 |
| 2020 | 1 | 5 | 6 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Repositioning" by people in Profiles.
-
A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cells. Med Oncol. 2024 Jun 25; 41(8):188.
-
The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant. Int J Mol Sci. 2023 Nov 03; 24(21).
-
Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing. Cell Rep Med. 2023 10 17; 4(10):101227.
-
Small-Molecule Drug Repurposing for Counteracting Phototoxic A2E Aggregation. ACS Chem Biol. 2023 10 20; 18(10):2170-2175.
-
Controlling cell proliferation by targeting cyclin-dependent kinase 6 using drug repurposing approach. Adv Protein Chem Struct Biol. 2023; 135:97-124.
-
Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy? Curr Med Chem. 2023; 30(16):1798-1812.
-
Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021 09; 597(7878):732-737.
-
Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype. EMBO Mol Med. 2021 10 07; 13(10):e13742.
-
Adhatoda Vasica attenuates inflammatory and hypoxic responses in preclinical mouse models: potential for repurposing in COVID-19-like conditions. Respir Res. 2021 Apr 06; 22(1):99.
-
Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling. Oncogene. 2021 03; 40(11):1974-1987.